OccuLogix suspends RHEO programme

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

The RHEO procedure is a specific method of apheresis — a treatment in which a patient's blood is drawn outside the body and specific compounds are removed before being returned to the body.

The RHEO procedure uses patented filtering technology to remove excess levels of macro-proteins and fatty components in the blood that have been associated with AMD. These substances, which are known to thicken the blood, decrease blood flow and cause damage to capillary vessels, include LDL cholesterol, fibrinogen and alpha-2-macroglobulin.

The company cited costs and development timelines as its reasons for suspending the programme.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Related Content
© 2023 MJH Life Sciences

All rights reserved.